Education
About Us
Working with TipRanks
Follow Us
Immutep (IMMP)
NASDAQ:IMMP
IMMP Stock Chart & Stats
$2.04
-$0.05(-2.44%)
At close: 4:00 PM EST
$2.04
-$0.05(-2.44%)
Day’s Range― - ―
52-Week Range$1.32 - $3.53
Previous CloseN/A
Volume50.42K
Average Volume (3M)164.46K
Market Cap
$402.46M
Enterprise Value$496.10M
Total Cash (Recent Filing)$99.13M
Total Debt (Recent Filing)$1.21M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Sep 02, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding147,372,130
10 Day Avg. Volume156,747
30 Day Avg. Volume164,463
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)2.53
Price to Sales (P/S)71.92
P/FCF Ratio-5.84
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue62.62
Enterprise Value/Gross Profit-6.63
Enterprise Value/Ebitda-6.10
Forecast
1Y Price Target
$9.00Price Target Upside341.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$18.63M
Bulls Say, Bears Say
Bulls Say
Stronger Cash Runway From Dr. Reddy’s LicensingThe Dr. Reddy’s licensing deal delivered a material upfront and milestone potential, boosting pro-forma cash to A$129.3m and extending runway into mid-2027. This reduces near-term refinancing pressure, funds registrational trials and gives management optionality to progress programs or negotiate better commercial terms.
Operational Progress In Registrational Phase III TACTI-004Rapid, global enrollment and activated sites across 27 countries show strong operational execution for a registrational program. Sustained trial progress increases the chance of a definitive readout, which is central to converting efti into a commercial asset and shifting Immutep toward revenue-generating operations.
Pipeline Diversification With Positive IMP761 Phase I DataPromising first-in-human data for IMP761 diversifies Immutep beyond oncology into autoimmune therapeutics. Early safety and biologic activity reduce program risk and create a separate value driver in a large market, improving strategic optionality for partnering or internal development over the medium term.
Bears Say
Persistent Negative Margins And Cash FlowOngoing negative gross, operating and net margins and continued operating/free cash outflows mean Immutep cannot self-fund growth from product revenues. This structural cash deficit increases reliance on external financing and could dilute shareholders or constrain R&D if partnerships slow.
Business Model Dependent On Partnerships And FinancingAs a clinical-stage biotech without commercial products, Immutep’s durable revenue depends on licensing deals, milestone receipts and equity raises. That model creates revenue volatility and execution risk: failed deals or weak market windows would materially impair funding and program progression.
Concentration Risk Around Efti Phase III OutcomeImmutep’s path to commercial-stage hinges heavily on a single registrational program (efti + pembrolizumab). A negative futility readout or disappointing endpoints would materially reduce near-term commercialization prospects and upside, magnifying downside for the company’s valuation and financing prospects.
Immutep News
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $1.32 and its highest was $3.53 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is $402.46M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Sep 02, 2026 which is in 183 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Aug 29, 2025. The company reported -$0.197 earnings per share for the quarter, missing the consensus estimate of -$0.186 by -$0.011.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.2.
How many shares outstanding does Immutep have?
Immutep has 147,372,130 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$0.197 in its last earnings report, missing expectations of -$0.186. Following the earnings report the stock price went down -3.012%.
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in IMMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (341.18% Upside)
$9.00 (341.18% Upside)
Blogger Sentiment
Bullish
IMMP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.34%
12-Months-Change
Fundamentals
Return on Equity
-62.72%
Trailing 12-Months
Asset Growth
-13.05%
Trailing 12-Months
Company Description
Immutep
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
IMMP Stock 12 Month Forecast
Average Price Target
$9.00
▲(341.18% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.33% Other Institutional Investors
99.09% Public Companies and
Individual Investors